










DEVELOPING TRANSFORMATIVE THERAPIES TO TREAT THE WHOLE EYE

Company Highlights

- NASDAQ: OCGN
- Strong global IP
- Diversified Portfolio with Three Waves of Technological Innovation

	Indication		Prevalence (US)	Preclinical	Phase 1	Phase 2	Phase 3
OCULAR SURFACE DISEASE (small molecule)							
OCU300	oGVHD	Orphan US	63,000				
MODIFIER GENE THERAPY PLATFORM							
OCU400 <small>AAV-NR2E3</small>	NR2E3 Mutation-Associated Retinal Degeneration	Orphan US	500-600				
	CEP290 Mutation-Associated Retinal Degeneration	Orphan US	2,500-3,000				
	RHO Mutation-Associated Retinal Degeneration		10,400-12,700				
OCU410 <small>AAV-RORA</small>	Dry AMD		9-10M				
RETINAL DISEASES (novel biologic)							
OCU200 <small>Tumstatin-Transferrin</small>	Diabetic Macular Edema		745,000				
	Diabetic Retinopathy		7.7M				
	Wet AMD		1.1M				

Quick Facts

Ticker:
OCGN (NASDAQ)

Employees:
16 at 4/13/20

Cash & Investments:
\$7.6M at 12/31/19

Location:
Malvern, PA

Shares Outstanding:
52.6M at 12/9/19

Strategic Partnership

Ocugen has entered into a strategic partnership with CanSino Biologics for the development of OCU400, Ocugen's first product candidate in its modifier gene therapy platform.

Collaboration paves a path for Ocugen to advance OCU400 into the clinic with significantly reduced capital and resources.



Seasoned Management Team

Shankar Musunuri, PhD, MBA
Chairman, CEO & Co-Founder

Dan Jorgensen, MD, MPH, MBA
Chief Medical Officer

Kelly Beck, MBA
VP, Investor Relations & Administration

Sanjay Subramanian, MBA
Chief Financial Officer

Rasappa Arumugham, PhD
Chief Scientific Officer

Vijay Tammara, PhD
SVP, Regulatory & Quality


OCU300: oGVHD

Proprietary nanoemulsion of brimonidine tartrate for the treatment of ocular redness and ocular discomfort in patients with oGVHD

- Phase 3, 84-day Randomized, Double-Masked, Placebo-Controlled Study
- 60 patients; 2:1 randomization
- Co-primary endpoints:
 - Symptom: Ocular discomfort based on Visual Analog Scale
 - Sign: Ocular redness based on Validated Bulbar Redness Score

OcuNanoE™ Drug Delivery System



Increases brimonidine in lacrimal gland and improves overall efficacy of OCU300



- OCU300 = Brimonidine (0.18%) OcuNanoE™
- Brimonidine = Commercial 0.2% solution
- Figure shows median, interquartile range, min/max fluorescein score
- **p<0.01

Modifier Gene Therapy

Introduce a functional gene to modify the expression of many genes, gene networks and reset homeostasis



Control Retinal Degeneration Mouse Models

30 days post-injection
rd16 is another name for CEP290 model

Mice Models represent different inherited retinal diseases

OCU200: Wet AMD, DME, DR

Tumstatin-Transferrin Fusion Protein offering benefits beyond Anti-VEGF

- First company focused on macromolecule (fusion protein) to target integrins for ocular diseases
- Integrin-targeting based approaches are actively explored in a variety of disease treatments, such as cancer, autoimmune, angiogenic and fibrotic treatments
- Selectively works on active endothelial cells; targeting element enhances effective concentration

Key Targeted Milestones

OCU300
ocular GVHD
(Phase 3 small molecule)

- Mar 2020: Over 95% Planned Enrollment Achieved
- 2H2020: Topline Results Expected

OCU400 (NR2E3-AAV)
Retinal Degenerative Diseases
(gene therapy)

- 2020: Continue IND-Enabling Studies
- 2020: Initiated Tox Studies
- 2021: Target Phase 1/2a Clinical Trial

OCU200
Wet AMD, DME, DR
(novel biologic)

- 2020-2021: Continue IND-Enabling Studies
- 2022 Target Phase 1/2a Clinical Trial



For more information, please contact:

Kelly Beck, Vice President, Investor Relations
+1 484.328.4698 | kelly.beck@ocugen.com | www.ocugen.com

Forward Looking Statement: This document contains forward-looking statements that involve substantial risks and uncertainties. These statements, among other things, relate to our business strategy, future results of operations and financial position, prospective products, product approvals, research and development costs, timing and likelihood of success, estimated market size or growth, and plans and objectives of management for future operations. When used in this presentation, the words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements involve known and unknown risks, uncertainties and other factors, including those risks set forth in the our filings with the Securities and Exchange Commission, which are available at www.sec.gov, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information available to management as of the date hereof. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.